European Journal of Integrative Medicine
Volume 1, Issue 1 , Pages 19-25 , April 2009

Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology

  • Oliver Micke

      Affiliations

    • Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Bielefeld, Germany
    • Corresponding Author InformationCorresponding author at: Klinik für Strahlentherapie und Radioonkologie, Franziskus Hospital, Kiskerstraße 26, D-33615 Bielefeld, Germany. Tel.: +495215891801; fax: +495215891804.
    • ,
  • Frank Bruns

      Affiliations

    • Department of Radiotherapy and Special Oncology, Hannover Medical School, Hannover, Germany
    • ,
  • Michael Glatzel

      Affiliations

    • Department of Radiotherapy, Suhl Central Hospital, Suhl, Germany
    • ,
  • Klaus Schönekaes

      Affiliations

    • Radiotherapy Practice, Minden, Germany
    • ,
  • Patrick Micke

      Affiliations

    • Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
    • ,
  • Ralph Mücke

      Affiliations

    • Department of Radiotherapy, St. Josef Hospital, Wiesbaden, Germany
    • ,
  • Jens Büntzel

      Affiliations

    • Department of Otolaryngology, Südharz Hospital, Nordhausen, Germany

Received 5 January 2009 ,Revised 27 January 2009 ,Accepted 9 February 2009.

References 

  1. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340:1733–1739
  2. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998;83:777–782
  3. Micke O, Büntzel J. Complementary and alternative medicine in tumor patients. A dilemma in modern oncology. Onkologe. 2008;14:73–80
  4. Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, et al. Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway. Eur J Cancer. 2004;40:529–535
  5. Risberg T, Lund E, Wist E. Use of non-proven therapies. Differences in attitudes between Norwegian patients with non-malignant disease and patients suffering from cancer. Acta Oncol. 1995;34:893–898
  6. NCCAM, What is complementary and alternative medicine (CAM)?, 2008. National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health.
  7. Lilienfeld SO. Our Raison d’Être. Sci Rev Ment Health Pract. 2002;1:1–2
  8. Malik IA, Gopalan S. Use of CAM results in delay in seeking medical advice for breast cancer. Eur J Epidemiol. 2003;18:817–822
  9. Cassileth BR, Deng GE, Gomez JE, Johnstone PA, Kumar N, Vickers AJ. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:340S–344S
  10. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246–252
  11. Ernst E, Cassileth BR. How useful are unconventional cancer treatments?. Eur J Cancer. 1999;35:1608–1613
  12. Micke O, Mucke R, Schonekaes K, Buntzel J. Complementary and alternative medicine in radiotherapy patients—more harm than expected? In regard to D’Amico et al.: self-administration of untested medical therapy for treatment of prostate cancer can lead to clinically significant adverse events. Int J Radiat Oncol Biol Phys. 2002;54:1311–1313
  13. Micke O, Mücke R, Bruns F, Kisters K, Buntzel J. Some clinical results on selenium in radiation oncology: letter by O. Micke, R. Mucke, F. Bruns, K. Kisters, J. Buntzel on W. Dorr: Effects of selenium on radiation responses of tumor cells and tissue in: Strahlenther Onkol 2006;182:693–5 (No. 12). Strahlenther Onkol. 2007;183:344–345
  14. von Gruenigen VE, Hopkins MP. Alternative medicine in gynecologic oncology: a case report. Gynecol Oncol. 2000;77:190–192
  15. Schönekaes K, Micke O, Mucke R, Buntzel J, Glatzel M, Bruns , et al. Use of complementary/alternative therapy methods by patients with breast cancer. Forsch Komplementarmed Klass Naturheilkd. 2003;10:304–308
  16. Burstein HJ. Discussing complementary therapies with cancer patients: what should we be talking about?. J Clin Oncol. 2000;18:2501–2504
  17. Evans MA, Shaw AR, Sharp DJ, Thompson EA, Falk S, Turton P, et al. Men with cancer: is their use of complementary and alternative medicine a response to needs unmet by conventional care?. Eur J Cancer Care (Engl). 2007;16:517–525
  18. Boon H, Brown J, Gavin A. What are the experiences of women with breast cancer as they decide whether to use complementary/alternative medicine?. West J Med. 2000;173:39
  19. Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol. 2000;18:2515–2521
  20. Vapiwala N, Mick R, Hampshire MK, Metz JM, DeNittis AS. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer. 2006;J12:467–474
  21. Schönekaes K, Schüller P, Micke O, Mücke R, Büntzel J, Bruns F, et al. An analysis of complementary/alternative medicine (CAM) use by radiotherapy patients. Trace Elem Electrolytes. 2001;18:181–185
  22. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;8:2505–2514
  23. Söllner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P. Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer. 2000;89:873–880
  24. Söllner W, Zingg-Schir M, Rumpold G, Fritsch P. Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. Arch Dermatol. 1997;133:316–321
  25. Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, et al. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med. 2002;2:8
  26. Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ, et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med. 2002;8:477–485
  27. Roberts CS, Baker F, Hann D, Runfola J, Witt C, McDonald J, et al. Patient–physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol. 2005;23:35–60
  28. Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135:262–268
  29. Paltiel O, Avitzour M, Peretz T, Cherny N, Kaduri L, Pfeffer RM, et al. Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol. 2001;19:2439–2448
  30. Tas F, Ustuner Z, Can G, Eralp Y, Camlica H, Basaran M, et al. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol. 2005;44:161–167
  31. Yildirim Y, Tinar S, Yorgun S, Toz E, Kaya B, Sonmez S, et al. The use of complementary and alternative medicine (CAM) therapies by Turkish women with gynecological cancer. Eur J Gynaecol Oncol. 2006;27:81–85
  32. Grothey A, Duppe J, Hasenburg A, Voigtmann R. Use of alternative medicine in oncology patients. Dtsch Med Wochenschr. 1998;123:923–929
  33. McKay DJ, Bentley JR, Grimshaw RN. Complementary and alternative medicine in gynaecologic oncology. J Obstet Gynaecol Can. 2005;27:562–568
  34. Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T. Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol. 1998;16:6–12
  35. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage. 2000;20:374–387
  36. Shumay DM, Maskarinec G, Gotay CC, Heiby EM, Kakai H. Determinants of the degree of complementary and alternative medicine use among patients with cancer. J Altern Complement Med. 2002;8:661–671
  37. Monti DA, Sufian M, Peterson C. Potential role of mind–body therapies in cancer survivorship. Cancer. 2008;112:2607–2616
  38. Glatzel M, Fröhlich D, Westhäuser S, Borschke D, Krauß A, Bäsecke S, et al. Komplementäre und alternative Medizin bei Strahlentherapiepatienten-regionale Unterschiede innerhalb Deutschlandes. [Complementary and alternative medicine (CAM) in radiotherapy patients—regional differences inside of Germany.]. Strahlenther Onkol. 2002;178(Suppl. 1):93
  39. Buentzel J, Muecke R, Schaefer U, Micke O. Use of complementary and alternative medicine (CAM) in head and neck cancer—is it really limited?. Laryngoscope. 2006;116:506–507
  40. Lerner IJ, Kennedy BJ. The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin. 1992;42:181–191
  41. Gertz MA, Bauer BA. Caring (really) for patients who use alternative therapies for cancer. J Clin Oncol. 2001;19:4346–4349
  42. Huber R, Koch D, Beiser I, Zschocke I, Luedtke R. Experience and attitudes towards CAM—a survey of internal and psychosomatic patients in a German university hospital. Altern Ther Health Med. 2004;10:32–36
  43. Münstedt K, Entezami A, Kullmer U. Oncologic mistletoe therapy: physicians’ use and estimation of efficiency. Dtsch Med Wochenschr. 2000;125:1222–1226
  44. Carlsson M, Arman M, Backman M, Hamrin E. Coping in women with breast cancer in complementary and conventional care over 5 years measured by the mental adjustment to cancer scale. J Altern Complement Med. 2005;11:441–447
  45. Ernst E. The role of complementary and alternative medicine in cancer. Lancet Oncol. 2000;1:176–180
  46. Ernst E. Alternative cancer cures. Br J Cancer. 2001;85:781–782
  47. Münstedt K, von Georgi R. Unconventional cancer therapies—comparisons of attitudes and knowledge between physicians in Germany and Greece. Forsch Komplementarmed Klass Naturheilkd. 2005;12:254–260
  48. Mücke R, Glatzel M, Reichl B, Bernd-Skorka R, Büntzel J, Bruns F, et al. Sodium selenite in gynecologic radiation oncology—results of a prospective randomised observation study. Trace Elem Electrolytes. 2006;23:173–176
  49. Efficace F, Horneber M, Lejeune S, Van Dam F, Leering S, Rottmann M, et al. Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. J Clin Epidemiol. 2006;59:1257–1265
  50. Markman M. Safety issues in using complementary and alternative medicine. J Clin Oncol. 2002;20:39S–41S
  51. Meijerman I, Beijnen JH, Schellens JH. Herb–drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006;11:742–752
  52. White AR, Ernst E. Economic analysis of complementary medicine: a systematic review. Complement Ther Med. 2000;8:111–118
  53. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280:1569–1575
  54. Richardson MA. Research of complementary/alternative medicine therapies in oncology: promising but challenging. J Clin Oncol. 1999;17:38–43
  55. Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, et al. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum. 2000;27:623–630
  56. Cassileth BR. Alternative and complementary cancer treatments. Oncologist. 1996;1:173–179
  57. Swarup AB, Barrett W, Jazieh AR. The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol. 2006;29:468–473

PII: S1876-3820(09)00005-5

doi: 10.1016/j.eujim.2009.02.001

European Journal of Integrative Medicine
Volume 1, Issue 1 , Pages 19-25 , April 2009

Article Tools

* Image Usage & Resolution